Showing 791-800 of 2293 results for "".
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- FDA Grants Fast Track Designation to Potential Treatment for Multiple System Atrophyhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-potential-treatment-for-multisystem-atrophy/2473790/Amlenetug (Lundbeck, Deerfield, IL), a monoclonal antibody (mAb) that targets extracellular α-synuclein, was granted Fast Track Designation (FTD) by the Food and Drug Administration (FDA) for investigation as a potential treatment for multiple system atrophy (MSA). According to a statement
- Phosphorylated α-Synuclein Detectable by Skin Biopsy in Those with Synucleionopathies Including Parkinson Diseasehttps://practicalneurology.com/news/phosphorylated-a-synuclein-detectable-by-skin-biopsy-in-those-with-synucleionopathies-including-parkinson-disease/2470436/According to study results published in JAMA, a high proportion of people with Parkinson disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF) showed skin biopsies positive for cutaneous phosphorylated α-synuclein. The result
- Ampreloxetine May Be Effective at Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophyhttps://practicalneurology.com/news/ampreloxetine-may-be-effective-at-treating-neurogenic-orthostatic-hypotension-in-patients-with-multiple-system-atrophy/2470280/Ampreloxetine (Theravance Biopharma, South San Francisco, CA) may be a safe and effective treatment for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) according to study results presented at the 2023 International Congress of Parkinson’s
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A
- Study Shows Mobile Stroke Units Lead to Better Outcomeshttps://practicalneurology.com/news/study-shows-mobile-stroke-units-lead-to-better-outcomes/2469684/A study published in The New England Journal of Medicine found that people with acute ischemic stroke had better outcomes when treated in a mobile stroke unit (MSU) instead of a standard emergency medical services (EM
- Mixed Sodium Oxybates Improve Idiopathic Hypersomniahttps://practicalneurology.com/news/mixed-sodium-oxybates-improve-idiopathic-hypersomnia/2469574/In a phase 3 study (NCT03533114) of mixed salt oxybates (MSO) (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for treatment of idiopathic hypersomnia (IH) showed improvement on multiple measures. All participants first received tr
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- Outcomes of Ischemic Stroke Care in Mobile Stroke Units Superior to Ambulanceshttps://practicalneurology.com/news/outcomes-of-ischemic-stroke-care-in-mobile-stroke-units-superior-to-ambulances/2469533/Data from the BEST-MSU study (NCT02190500) presented at the International Stroke Conference, held online March 17-19, 2021, showed care for individuals with ischemic stroke in mobile stroke units (MSUs) was superior compared with stand
- Nanocatalytic Gold Treatment Improves Multiple Sclerosis Functional Composite Scores in Phase 2 Studieshttps://practicalneurology.com/news/nanocatalytic-gold-treatment-improves-multiple-sclerosis-functional-composite-scoresin-phase-2-studies/2469513/Treatment with the bioenergetic catalyst nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) improved Multiple Sclerosis Functional Composite (MSFC) scores significantly more than placebo. Participants in the trial continued taking disease-modifying treatments approved for the